ARA-290 (Cibinetide): Innate Repair Receptor Mechanism, Literature, and Verification

Most research peptides begin their story as fragments of something larger, and ARA-290 is an unusually elegant example. It is an eleven-amino-acid sequence lifted directly from a single surface of the erythropoietin molecule — the hormone best known for driving red blood cell production — but engineered specifically to leave that hematopoietic function behind. What remains is a compact peptide that engages a distinct tissue-protective receptor system, a target that only appears on cells under stress. For a laboratory building a reference library around inflammation resolution, neuroprotection, or receptor-restricted signaling, ARA-290 (also known by its International Nonproprietary Name, cibinetide) is one of the more mechanistically well-defined tool compounds available. This guide surveys it strictly at the molecular and preclinical level: what it is, how it is understood to act at the receptor and pathway level, what the primary literature actually reports, and how a research group should evaluate the material it sources.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes. ARA-290 is an investigational compound and is not approved by the FDA for any indication.

Section 1 — Molecular Profile

ARA-290 is a short, linear peptide derived from the aqueous-facing region of helix B of erythropoietin (EPO). Erythropoietin’s red-cell-stimulating activity depends on one face of the molecule binding the classical EPO receptor homodimer; the tissue-protective activity is mediated by a separate, spatially distinct surface. ARA-290 was designed to reproduce that second surface in isolation, giving researchers a molecule that engages the protective pathway without touching the erythropoietic one.

ARA-290 (cibinetide)
– CAS number: 1208243-50-8
– Molecular formula: C51H84N16O21
– Molecular weight: approximately 1257.3 g/mol (1257 Da)
– Length: 11 amino acids
– Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (with an N-terminal pyroglutamate)
– PubChem CID: 91810664
– Class: erythropoietin-derived, non-erythropoietic innate repair receptor agonist

The N-terminal pyroglutamate is worth noting for anyone characterizing the material: it is a cyclized glutamine residue that caps the amino terminus and is a genuine structural feature of the sequence rather than a synthesis artifact, so an analyst should expect it when confirming identity by mass. The peptide is water-soluble and is typically supplied as a lyophilized acetate salt for reconstitution in aqueous buffer. Like most short linear peptides it is susceptible to peptidase degradation, which is one reason the preclinical literature has explored the durability of its signaling relative to native EPO. Its comparatively modest length — eleven residues — makes it tractable to synthesize and characterize, but that same length means truncation and deletion sequences are the impurities most worth screening for.

Section 2 — Mechanism

The mechanistic story of ARA-290 is genuinely one of the cleaner ones in the peptide-research space, because it was designed around a specific receptor hypothesis rather than discovered empirically and rationalized afterward. The central concept is the innate repair receptor (IRR), sometimes called the tissue-protective receptor. This is not the classical erythropoietin receptor. It is a heterocomplex assembled from one EPO-receptor subunit paired with the beta-common receptor (CD131) — the same signal-transducing subunit shared by the GM-CSF, IL-3, and IL-5 receptor families. Native erythropoietin can bind this heteroreceptor, but only transiently and at concentrations higher than those needed for erythropoiesis, which is why a purpose-built ligand became useful.

The defining property of the IRR is that it is not constitutively expressed. In the preclinical literature it is described as being up-regulated locally on cells that are stressed, injured, hypoxic, or inflamed, rather than being present at rest across healthy tissue. This is the feature that makes ARA-290 mechanistically distinctive: because the receptor appears only where tissue is under duress, an agonist for it behaves as a context-restricted signal that is, in principle, engaged at sites of active injury and largely silent elsewhere. In model systems, engagement of the IRR has been associated with anti-apoptotic signaling through the PI3K/Akt and JAK2/STAT pathways, dampening of pro-inflammatory cytokine cascades, and modulation of the local inflammatory-to-reparative transition — without the JAK2-driven erythropoietic signaling that the classical receptor produces.

Everything in this article stays at exactly that level: an erythropoietin-derived peptide that selectively engages the EPO-receptor/CD131 heterocomplex, activates cytoprotective and anti-inflammatory intracellular cascades in stressed cells, and does not stimulate red-cell production. Those are pathway- and receptor-level descriptions of activity observed in cell and animal models, not statements about clinical effect.

Section 3 — Preclinical Research Data

The preclinical foundation for ARA-290 predates the peptide itself, in the work that established that EPO’s tissue-protective and erythropoietic activities are pharmacologically separable. The concept that a distinct EPO-receptor/beta-common heteroreceptor mediates cytoprotection, rather than the classical erythropoietic receptor, is what made a non-erythropoietic derivative conceivable at all, and it defined the target ARA-290 was built to hit.

From that foundation, a body of animal-model work examined the peptide’s activity in neuropathic and inflammatory injury systems. A frequently cited experimental study in rats and neuroblastoma cell lines reported that ARA-290 produced durable relief of neuropathic-pain behavior in a spared-nerve-injury model, with the effect tied to the peptide’s action on the tissue-protective pathway rather than to any erythropoietic activity — and, importantly, without the increase in red-cell mass that limits native EPO as a research tool. This combination of a reproducible functional readout in a well-defined injury model plus a clean separation from hematopoietic signaling is what established ARA-290 as a usable probe for IRR biology.

Across the broader preclinical record, ARA-290 has been studied in models of ischemia-reperfusion injury, inflammatory tissue damage, and metabolic stress, with the recurring observation being reduced markers of apoptosis and inflammation in the affected tissue. The through-line is consistent with the mechanism: a receptor that is induced by injury, an agonist that engages it selectively, and downstream readouts that track cytoprotection and inflammation resolution rather than proliferation. For a laboratory, the value of the compound is precisely this specificity — it isolates the tissue-protective arm of EPO signaling from the erythropoietic arm in a single small molecule.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for an ARA-290 research library. Several describe investigational clinical studies; they are cited here as part of the scientific record, not as evidence of any outcome associated with research-grade material:

• Brines M, Grasso G, Fiordaliso F, et al. “Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.” Proceedings of the National Academy of Sciences USA, 2004; 101(41):14907-14912.
• Brines M, Patel NSA, Villa P, et al. “Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.” Proceedings of the National Academy of Sciences USA, 2008; 105(31):10925-10930.
• Swartjes M, Morariu A, Niesters M, et al. “ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and neuroblastoma cell lines.” Anesthesiology, 2011; 115(5):1084-1092.
• Brines M, Cerami A. “The receptor that tames the innate immune response.” Molecular Medicine, 2012; 18(1):486-496.
• Heij L, Niesters M, Swartjes M, et al. “Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, blinded pilot study.” Molecular Medicine, 2012; 18(1):1430-1436.
• Dahan A, Dunne A, Swartjes M, et al. “ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.” Molecular Medicine, 2013; 19(1):334-345.
• Culver DA, Dahan A, Bajorunas D, et al. “Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain.” Investigative Ophthalmology & Visual Science, 2017; 58(6):BIO52-BIO60.

These references trace ARA-290 from the receptor biology that justified its design, through the animal-model work that characterized its activity, to the investigational clinical studies that used structural endpoints such as corneal nerve fiber density measured by confocal microscopy. Together they form the primary literature a research group needs to design and interpret in-vitro work on the peptide.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, ARA-290 is studied for a set of overlapping, model-system purposes:

• Innate repair receptor pharmacology: as a selective ligand for probing the EPO-receptor/CD131 heterocomplex independently of the classical erythropoietic receptor, including binding and downstream-signaling studies in cell lines.
• Cytoprotection and apoptosis signaling: measuring anti-apoptotic pathway activation (PI3K/Akt, JAK2/STAT) and cell-survival readouts in stressed or injured cell cultures.
• Inflammation-resolution models: characterizing effects on pro-inflammatory cytokine output and the inflammatory-to-reparative transition in immune and tissue-cell models.
• Neuroprotection assays: as a comparator compound in neuronal and neuroblastoma culture systems examining stress-induced injury.
• Structure-activity and separation-of-function studies: using ARA-290 as the reference “non-erythropoietic” derivative against which native EPO and other analogs are compared for tissue-protective versus hematopoietic activity.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade ARA-290 is supplied as a research chemical rather than a finished pharmaceutical preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage figure — important for an eleven-residue peptide where truncated and deletion sequences are the most common synthesis impurities.
• LC-MS or MS identity confirmation of the ~1257 Da target mass. Because the sequence carries an N-terminal pyroglutamate cap, correct identity confirmation should reflect that modified terminus rather than a free-glutamine mass, which is a useful tell that the analyst characterized the intended molecule.
• Endotoxin and heavy-metal testing for lyophilized material intended for cell-based work, since bacterial endotoxin independently activates inflammatory and apoptotic pathways and would directly confound any cytoprotection or inflammation-resolution assay.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, ARA-290 generally trades at a moderate research-chemical price point — commonly in the range of roughly $40–$70 for a 10 mg lyophilized vial across suppliers — reflecting a mid-length synthetic peptide of moderate complexity. Price alone says nothing about identity or purity; only third-party analytical data does. Because the compound’s entire research value rests on it being the intact, correctly capped eleven-residue sequence rather than a fragment, orthogonal identity testing matters more here than for a simpler peptide, not less.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a peptide like ARA-290, orthogonal identity testing is what separates the genuine, pyroglutamate-capped eleven-residue sequence from a truncated fragment or a mis-synthesized analog. Because the compound’s mechanistic specificity — engaging the innate repair receptor without erythropoietic activity — depends on the intact sequence, LC-MS confirmation of the ~1257 Da target mass, not just a purity percentage, is the only way to verify that a vial contains full-length ARA-290. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/ara-290/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.